Business Context and Reporting Period
Caribou Biosciences, Inc. filed this Form 8-K on July 13, 2023, to report the entry into a material definitive agreement for a public offering of common stock. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
- Offering Size: 19,230,769 shares of common stock.
- Public Price: $6.50 per share.
- Underwriter Price: $6.11 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 2,884,615 additional shares.
- Expected Net Proceeds: Approximately $116.9 million (excluding over-allotment exercise).
- Underwriters: BofA Securities, Inc., SVB Securities LLC, and Evercore Group L.L.C.
- Expected Closing Date: On or about July 18, 2023.
This filing does not provide revenue, profit, cash flow, margin, or debt metrics for the reporting period.
Material Changes
The primary material change is the execution of an underwriting agreement to raise capital. The offering was initially proposed at $100 million but was upsized to approximately $125 million (gross) prior to pricing. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the anticipated closing of the offering and the amount of net proceeds. Management notes that the closing is subject to customary conditions. Risks include the company's ability to satisfy closing conditions on a timely basis or at all. No specific operational guidance or outlook beyond the capital raise is provided in this document.
Investor Verification Checklist
- Verify the final closing date and confirmation of net proceeds received.
- Check if the underwriters exercised the 30-day over-allotment option for an additional 2,884,615 shares.
- Review the final prospectus supplement for updated use of proceeds and risk factors.
- Monitor subsequent filings for the impact of this capital raise on the company's cash runway and liquidity position.